DOCS: Healthcare Moat And AI Investment Year Will Drive Future Engagement

Analyst price targets for Doximity have been reset lower, with the internal fair value estimate moving from $37.77 to $25.15 as analysts factor in slower projected revenue growth, softer profit margins, and a reduced future P/E multiple amid industry wide concerns about digital ad spending, rising competition, and uncertain payoffs from heavier AI investment.

Analyst Commentary

Street research has turned more cautious on Doximity following its recent results and fiscal 2027 outlook, with many firms cutting price targets and, in several cases, downgrading ratings. Even so, opinions are not one sided, and there is a clear split between analysts who still see long term value in the business and those who are focused on execution risk and slower growth expectations.

Bullish Takeaways

Bullish analysts who maintain Buy or Outperform ratings highlight Doximity's potential as a healthcare specific platform with strong network effects. They see this as a supportive foundation for long term growth and operating leverage as the model scales.
Some view the current period as an investment phase in AI, with initiatives such as the AI Search product for pharma and a broader healthcare AI strategy seen as potential drivers of new budget and future monetization, even though the near term impact on margins is negative.
Supportive analysts frame the pullback in the stock and lower price targets, such as the US$31 level cited by Freedom Capital or the US$30 and US$27 levels set by selected firms, as resetting expectations rather than abandoning the case that Doximity can still be an AI winner in its niche.
Even where target cuts are meaningful, some analysts still see value in the shares relative to their revised fair value estimates. They point to the combination of a profitable core business and the option value of successful AI commercialization over time.

Bearish Takeaways

Bearish analysts emphasize that Doximity's fiscal 2027 guidance is well below prior expectations. Multiple firms state that revenue growth visibility has weakened and that the company is transitioning from a clear growth leader to a more mature, challenged platform.
Several reports flag rising competitive pressure, including from healthcare IT peers and companies such as Veeva, along with pharma marketing platforms that are also leaning into AI. This raises concerns about incremental share erosion and the ability to defend premium offerings.
Heavier AI investment is a common concern, with firms like Goldman Sachs and Wells Fargo highlighting that higher compute and development costs are compressing margins before there is clear proof of revenue uplift. This leaves investors focused on execution risk and the timing of any AI payoffs.
Many cautious voices point to softer digital advertising trends, shorter term client planning cycles, and macro headwinds as reasons why digital marketing and healthcare IT companies can see depressed valuations for prolonged periods, especially when near term growth is limited and catalysts are scarce.

What's in the News

Doximity reported fiscal Q4 2026 revenue of US$145.4 million, a 5% year over year increase versus consensus, with adjusted EPS of US$0.26 compared with expectations of US$0.28, record free cash flow of US$107 million, and cautious fiscal 2027 revenue guidance of US$664 million to US$676 million that was below prior Wall Street estimates, according to multiple earnings reports.
Shares of Doximity fell over 23% to 26% after recent earnings releases and guidance, as investors reacted to slower expected growth, higher AI related spending, and weaker pharma advertising trends, based on post earnings trading coverage.
The Schall Law Firm announced a securities investigation into Doximity focused on whether the company made false or misleading statements or omitted key information to investors following the May 13, 2026 results, according to the firm's public release.
Doximity issued guidance for fiscal Q1 2027 revenue of US$151 million to US$152 million and full year fiscal 2027 revenue of US$664 million to US$676 million, according to company guidance disclosures.
Doximity appointed Matthew Sonefeldt as Chief Financial Officer effective June 8, 2026, following the earlier medical leave and resignation of former CFO Anna Bryson and the interim tenure of Chief Accounting Officer Siddharth Sitaram, as disclosed in company executive change announcements.

Valuation Changes

Fair Value: the internal fair value estimate has been reduced from $37.77 to $25.15, representing a significant reset in the implied valuation.
Discount Rate: the discount rate has moved slightly lower from 8.25% to 8.02%, reflecting a modest change in the required return assumption.
Revenue Growth: the long term revenue growth assumption has been cut from 7.04% to 6.05%, indicating more conservative expectations for top line expansion.
Net Profit Margin: the net profit margin assumption has been reduced from 31.89% to 27.59%, suggesting a less generous view on future profitability.
Future P/E: the future P/E multiple has been lowered from 33.61x to 25.40x, implying a smaller valuation premium on projected earnings.

5 views

Key Takeaways

AI-powered workflow tools and high platform engagement drive deeper customer retention, higher revenue per user, and expanding long-term margins.
Broad client demand and digital marketing trends position Doximity for sustained growth, improved sales efficiency, and earnings stability through diversified revenue streams.
Heavy short-term investment in free AI features, dependence on pharma marketing, regulatory risks, and slowing user growth could constrain revenue, margin, and earnings expansion.

Catalysts

About Doximity

Operates as a digital platform for medical professionals in the United States.What are the underlying business or industry changes driving this perspective?

The expanded adoption of AI-powered workflow tools (Scribe, Doximity GPT, and Pathway AI) is expected to further entrench Doximity as a core clinician productivity suite, driving frequency of platform use, deeper customer retention, and ultimately higher average revenue per user (ARPU) over time-supporting long-term revenue and margin expansion.
Strong, broad-based demand from pharmaceutical, SMB, and health system clients-fueled by a digital-first shift in pharma marketing strategies and expansion of self-service/commercial portals-positions Doximity for sustained top-line growth, particularly as digital advertising continues supplanting traditional outreach, bolstering both revenue growth and sales efficiency.
The stickiness and daily-use nature of Doximity's telehealth, scheduling, and workflow tools-amplified by ongoing healthcare workforce shortages-reinforce Doximity's value proposition and increase switching costs, supporting resilient net revenue retention (>118%) and reducing future churn, which underpins stable earnings and improving EBITDA margins.
Growing penetration and upsell to enterprise health systems (including 17 of the top 20 U.S. systems) and accelerated momentum in recruitment/curative products leverages the regulatory and industry push toward digital, efficient, value-based care solutions, expanding addressable market and diversifying revenue streams, contributing to greater earnings visibility and lower cyclicality.
Internal and product-facing AI initiatives are driving meaningful productivity gains and operational leverage (headcount flat while revenue grows, AI-enabled client portal efficiency), which is likely to support further EBITDA margin expansion and robust free cash flow, even as the company invests heavily in new growth vectors.

Doximity Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Doximity's revenue will grow by 6.0% annually over the next 3 years.
Analysts assume that profit margins will shrink from 30.4% today to 27.6% in 3 years time.
Analysts expect earnings to reach $212.2 million (and earnings per share of $1.27) by about June 2029, up from $196.1 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $250.6 million in earnings, and the most bearish expecting $167.1 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 25.4x on those 2029 earnings, up from 19.2x today. This future PE is lower than the current PE for the US Healthcare Services industry at 30.1x.
Analysts expect the number of shares outstanding to decline by 2.36% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.02%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

While Doximity is successfully launching AI products like Scribe and integrating new acquisitions, management's decision to offer key advanced features (e.g., Scribe, Pathway corpus, DocsGPT) for free in the near-term could limit direct revenue growth and slow the monetization of its third act; this may delay the positive financial impact typically expected from new product launches, constraining revenue and earnings expansion in the medium term.
Doximity's continued heavy reliance on pharmaceutical marketing spend as its primary revenue driver exposes it to risks from regulatory or policy changes such as potential direct-to-consumer (DTC) bans, industry consolidation, or reduced pharma budgets, which could materially impact top-line growth and profitability over the long run.
The company is experiencing strong broad-based client and user engagement growth, but mentions of "policy uncertainty" and the need for "measured guidance" in the second half of the year highlight ongoing vulnerability to regulatory and healthcare budget fluctuations, introducing uncertainty into renewal rates, revenue predictability, and net margins.
While user engagement metrics are hitting record highs, a significant portion of physician adoption may plateau in the coming years as the platform nears saturation among U.S. clinicians; this dynamic can limit future network effect-driven growth, constricting both revenue momentum and margin leverage opportunities over the longer term.
Although management expects AI investments to drive long-term efficiency, current and upcoming stock-based compensation ("high teens" as a percentage of revenue through 2027) and ongoing OpEx increases for AI personnel and infrastructure may pressure net margins, dilute EPS, and offset some near-term gains from operational scale, particularly if new monetization from AI features lags expectations.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $25.15 for Doximity based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $42.0, and the most bearish reporting a price target of just $18.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $769.1 million, earnings will come to $212.2 million, and it would be trading on a PE ratio of 25.4x, assuming you use a discount rate of 8.0%.
Given the current share price of $20.59, the analyst price target of $25.15 is 18.1% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Doximity?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks